In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors

Current Opinion in Infectious Diseases

Volumn 11, Issue 6, 1998, Pages 727-732

  Mendel, Dirk B ^a   Roberts, Noel A ^b  

^a GILEAD SCIENCES   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; HONG KONG; HUMAN; INFLUENZA; META ANALYSIS; MORTALITY; NONHUMAN; REVIEW; VIRUS STRAIN;

EID: 0032435094     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199812000-00013     Document Type: Review

References (42)

1. von Itzstein M, Wu WY, Kok GB, Pegg MS, Cyason JC, Jin B. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-423.
2. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119:681-690. This paper details the discovery of GS4071, including the X-ray crystallographic data demonstrating that GS4071 binds to a previously unrecognized hydrophobic pocket in the active site of the neuraminidase enzyme.
3. Woods JM, Bethell RC, Coates JAV, Healy N, Hiscox SA, Pearson BA, et al. 4-guanidino-2,4-dideoxy-2,3dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37:1473-1479.
4. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42:640-646. The authors describe the in-vitro activity of GS4071 against neuraminidases from a variety of viral, bacterial, and mammalian sources, and the activity of oral GS4104 in the mouse and ferret models of influenza virus infection.
5. Mendel DB, Sidwell RW. Influenza virus resistance to neuraminidase inhibitors. Drug Resist Updates 1998; 1:184-189. This paper reviews the mechanisms and specific mutations that are responsible for the development of resistance to neuraminidase inhibitors. The authors conclude that resistance is difficult to generate in vitro, and that resistance to these drugs is unlikely to limit their clinical usefulness.
6. Barnett J, Dempsey M, Tisdale M, Rothbarth PH, De Groot R, Osterhaus ADME. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor Zanamivir (GG 167) during phase II clinical efficacy trials. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy; 28 September-1 October 1997; Toronto, Ontario, Canada [abstract].
7. Osterhaus ADME, Tisdale M, Elliott M. A double blind randomized trial of zanamivir in the treatment of acute influenza - clinical and virological efficacy results. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract].
8. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275:295-299.
9. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2En. J Virol 1996; 70:1818-1827.
10. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal WJ, Hornback JE, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995; 214:642-646.
11. Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, Hart GJ, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2En. Virology 1995; 214:475-484.
12. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, et al. Characterization of human influenza variants selected in vitro in the presence of the neuraminidase inhibitor GS4071. Antimicrob Agents Chemother 1998; in press:.
13. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71:3385-3390.
14. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72:2456-2462.
15. Penn CR, Barnett JM, Bethell RC, Fenton R, Gearing KL, Healy N, et al. Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in haemagglutinin may compensate for loss of neuraminidase activity In: Options for the control of influenza III. Brown LE, Hampson AW, Webster RG (editors). Amsterdam: Elsevier; 1996. pp. 735-740.
16. Ryan MD, Ticehurst J, Dempsey MH, Penn CR. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994; 38:2270-2275.
17. Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong M-H, Morrison A, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998; 37:107-120. The authors report results which demonstrate that oral administration of GS4104 inhibits virus replication and protects mice against death following infection with influenza virus.
18. Ryan MD, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoexy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995; 39:2583-2584.
19. Roberts NA, Carr JC, Lambkin R, Kelly L, Oxford JS. Oral administration of the neuraminidase inhibitor prodrug GS4104 blocks influenza virus replication in ferrets. European Respiratory Society Annual Congress; 19-23 September 1998; Geneva, Switzerland [abstract].
20. Fenton RJ, Owens I, Morley P, Penn CR. Influenza A virus infected ferrets, successfully treated with GG167, remain resistant to rechallenge with homologous virus, but are susceptible to heterologous influenza B virus challenge. Options for the Control of Influenza III; 4-9 May 1996; Cairns, Australia [abstract].
21. Sidwell RW, Burger RA, Huffman JH, Bailey KW, Warren RP. Immunological effects of the orally administered neuraminidase inhibitor GS4104 in influenza virus-infected and uninfected mice. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract].
22. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, et al. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071. Antimicrob Agents Chemother 1998; 42:647-653. The authors describe the oral bioavailabilities of GS4071 and its ethyl ester prodrug GS4104 in animals, and conclude that GS4104 has the potential to be an oral agent to prevent and treat influenza illness.
23. Wiltshire HR, Muir J, Lambkin R, Davies S. Distribution of the influenza neuraminidase inhibitor, GS4071, following oral administration of its prodrug GS4104 in ferrets. European Society for Clinical Virology; 30 August-2 September 1998; Hamburg, Germany [abstract].
24. Cundy KC, Eisenberg G, Bidgood A, Lynch G, Lee WA. Enhanced delivery of the novel influenza neuraminidase inhibitor GS4071 to rat lung after oral administration of the prodrug GS4104. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy; 28 September-1 October 1997; Toronto, Ontario, Canada [abstract].
25. Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997; 41:1949-1952. The authors present evidence that after oral administration of the prodrug GS4104 to rats the active moeity GS4071 is present in the secretions of the respiratory tract at concentrations sufficient to inhibit influenza neuraminidase activity.
26. Newman SP, Brown J, Pickford M, Fayinka S, Cass L. Deposition pattern in the respiratory tract of the neuraminidase inhibitor zanamivir; a gamma scintigraphic study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy; 28 September-1 October 1997; Toronto, Ontario, Canada [abstract].
27. Hussey EK, Moore KHP, Grosse G, Hirst HM, Eason CU, Yuen GJ. GG167 serum concentrations in influenza infection following intranasal and inhaled administration. Options for the Control of Influenza III; 4-9 May 1996; Cairns, Australia [abstract].
28. Efthymiopoulos C, Barrington P, Patel J, et al. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG 167) following intravenous, intranasal and inhaled administration in man. 34th Interscience Conference of Antimicrobial Agents and Chemotherapy; 4-7 October 1994; Orlando, Florida, USA [abstract].
29. Wood ND, Aitken M, Sharp S, Evison H. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro64-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy; 28 September-1 October 1997; Toronto, Ontario, Canada [abstract].
30. Algranati NE, Massarella JW, Wood ND, Rana B, Aitken M, Freestone S, et al. Pharmacokinetics and tolerability of the influenza neuraminidase inhibitor Ro 64-0802 following multiple dose oral administration of the prodrug Ro 64-0796 to healthy young and elderly subjects. European Respiratory Society Annual Congress; 19-23 September 1998; Geneva, Switzerland [abstract].
31. Hayden FG, Lobo M, Treanor JJ, Miller M, Mills RG. Efficacy and tolerability of oral GS4104 for early treatment of experimental influenza in humans. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy; 28 September-1 October 1997; Toronto, Ontario, Canada [abstract].
32. Calfee DP, Peng AW, Cass LMR, Lobo M, Hayden FG. Protective efficacy of intravenous zanamivir in experimental human influenza. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract].
33. Treanor JJ, Betts RF, Kallas E, Evans T, Hayden FG, Schultz-Cherry S, et al. Oral GS4014 prevents experimental infection of humans with influenza A (H1N1) virus. European Respiratory Society Annual Congress; 19-23 September 1998; Geneva, Switzerland [abstract].
34. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defence. J Clin Invest 1998; 101:643-649.
35. Hayden FG, Fritz RS, Lobo M, Kinnersley N, Mills RG, Straus SE. Effects of the oral neuraminidase inhibitor GS4104 on cytokine responses during experimental human influenza A virus infection. 11th Conference on Antiviral Research; 5-11 April 1998; San Diego, California, USA [abstract].
36. Fritz RS, Hayden FG, Clafee DP, Cass LMR, Peng AW, Alvord WG, et al. Cytokine and chemokine responses during experimental influenza A infection: effect of intravenous zanamivir. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract].
37. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337:874-880. This paper reports the first results of zanamivir in acute influenza infection, showing that administration intranasally or by inhalation was well tolerated, and that treatment reduced symptoms of influenza if initiated early.
38. Silagy CA, Campion KJ, Keene O. The effacacy and safety of Zanamivir in the treatment of influenza in otherwise healthy and 'high risk' individuals. 378th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract].
39. Aoki F, Osterhaus A, Rimmelzwaan G, Kinnersley N, Ward P. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract]. This abstract describes the first results from a large phase III study in Europe, Canada and China demonstrating that GS4104 is effective and well tolerated in natural influenza. Benefits were even greater when the therapy was initiated early.
40. Treanor JJ, Vrooman PS, Hayden FG, Kinnersley N, Ward P, Mills RG. Efficacy of oral GS4104 in treating acute influenza. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract]. The preliminary results of a large phase III US trial, confirming the safety and efficacy of this oral neuraminidase inhibitor.
41. Monto AS, Robinson DP, Herlocher L, Hinson JM, Elliott M, Keene O. Efficacy and safety of Zanamivir in prevention of influenza among healthy adults. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract].
42. Hayden FG, Atmar R. Schilling M, Johnson C, Poretz D, Parr D, et al Safety and efficacy of oral GS4104 in longterm prophylaxis of natural influenza. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, California, USA [abstract].